GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-15. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
== Properties == Cyclo Olefin Polymer (COP) has superior physical properties that make it well suited for medical and optical applications. It exhibits high purity, low extractables and leachables, has low surface energy, and it is chemically inert. Various fabrication methods can be used including compression molding, injection molding, laser ablation, and film extrusion to name a few. It is compatible with sterilization methods including newly developed NO2 processes. COP has exceptional optical clarity and exhibits extremely low birefringence which makes it well suited for optical applications such as virtual reality. COP and COC are not compatible with non-polar solvents but have good chemical resistance to other solvents, acids and bases.
=== Natural production === Natural vanillin is extracted from the seed pods of Vanilla planifolia, a vining orchid native to Mexico, but now grown in tropical areas around the globe. Madagascar is presently the largest producer of natural vanillin.
T4 (levothyroxine) is almost always preferred over T3 (liothyronine) when treating hypothyroidism. Treatment with T3 alone is not recommended, as it causes increased and potentially unsafe blood levels of free T3 (FT3). Combination treatment of hypothyroidism with T4 and T3 is generally only considered when treatment with T4 alone does not sufficiently resolve symptoms. As there is no evidence showing that combination treatment with T4 and T3 benefits patients, this approach is controversial, but it is supported by current guidelines of the European Thyroid Association and the British Thyroid Association for patients who do not respond at all to treatment with T4 alone.
== Interactions == The MC4 receptor has been shown to be activated by peptide hormones encoded by proopiomelanocortin (POMC). POMC is a precursor peptide pro-hormone which is cleaved into several other peptide hormones. All of the endogenous ligands of MC4 are produced by cleaving this one precursor peptide. These endogenous agonists include α-MSH, β-MSH, γ-MSH, and ACTH.
Sources: en.wikipedia.org
=== Further processing === The fat from whey is removed and then processed for human foods (see whey butter). Processing can be done by simple drying, or the relative protein content can be increased by removing lipids and other non-protein materials. For example, spray drying after membrane filtration separates the proteins from whey. Heat denatures whey proteins, causing them to coagulate into a protein gel that may be useful in some foods. Sustained high temperatures above 72 °C can denature whey proteins. Heat-denatured whey can still cause allergies in some people.
In order for this application to be successful, assorted surface functional groups are necessary and can be added either by the co-condensation process during preparation or by post surface modification. The high surface area of silica nanoparticles allows them to carry much larger amounts of the desired drug than through conventional methods like polymers and liposomes. It allows for site specific targeting, especially in the treatment of cancer. Once the particles have reached their destination, they can act as a reporter, release a compound, or be remotely heated to damage biological structures in close proximity. Targeting is typically accomplished by modifying the surface of the nanoparticle with a chemical or biological compound. They accumulate at tumor sites through Enhanced Permeability Retention (EPR), where the tumor vessels accelerate the delivery of the nanoparticles directly into the tumor. The porous shell of the silica allows control over the rate at which the drug diffuses out of the nanoparticle. The shell can be modified to have an affinity for the drug, or even to be triggered by pH, heat, light, salts, or other signaling molecules. Silica nanoparticles are also used in bio imaging because they can accommodate fluorescent/MRI/PET/ SPECT contrast agents and drug/DNA molecules to their adaptable surface and pores. This is made possible by using the silica nanoparticle as a vector for the expression of fluorescent proteins.
=== Fa–Fi === Kazimierz Fajans (1887–1975), Polish-American physical chemist, who worked on radioactivity and co-discovered protactinium Michael Faraday (1791–1867), British chemist and physicist who discovered include the principles of electromagnetic induction, diamagnetism, and electrolysis Hermann von Fehling (1812–1885), German chemist who developed use of Fehling's solution for estimation of sugar John Bennett Fenn (1917–2010), 2002 Nobel Prize in Chemistry for work in mass spectrometry Enrico Fermi (1901–1954), Nuclear chemist and elementary particle physicist, Nobel Prize in Physics 1938 Louis Fieser (1899–1977), American chemist who work on blood-clotting agents including the first synthesis of vitamin K, and was the author of numerous textbooks Mary Peters Fieser (1909–1997), American chemist who worked on quinones and steroids, and was co-author of chemistry books Barbara J. Finlayson-Pitts (PhD 1973), Canadian-American chemist who works on the chemistry of the upper and lower atmosphere Emil Fischer (1852–1919), 1902 Nobel Prize in Chemistry, known for work on stereochemistry and for the lock and key mechanism of enzyme action Emily V.
Shortness of breath, particularly with exertion Chronic dry, hacking coughing Fatigue and weakness Chest discomfort, including chest pain Loss of appetite and rapid weight loss Pulmonary fibrosis is suggested by a history of progressive shortness of breath (dyspnea) with exertion. Sometimes fine inspiratory crackles can be heard at the lung bases on auscultation. A chest X-ray may not be abnormal, but high-resolution CT will often show abnormalities.
== Treatment == Treatment for AGAT and GAMT mainly consists of creatine supplementation. GAMT treatment may also include ornithine and sodium benzoate supplementation and/or diet restrictions in arginine and/or protein. These have shown to be effective, especially when started early in life. There is no current effective treatment for CTD. Creatine supplementation can have some benefit but because creatine does not easily pass the blood-brain barrier without a functioning transporter, neurological symptoms remain significant.
Sources: en.wikipedia.org
==== 1914–1916: Initial Zionist–British Government discussions ==== In July 1914, war broke out in Europe between the Triple Entente (Britain, France, and the Russian Empire) and the Central Powers (Germany, Austria-Hungary, and, later that year, the Ottoman Empire). The British Cabinet first discussed Palestine at a meeting on 9 November 1914, four days after Britain's declaration of war on the Ottoman Empire, of which the Mutasarrifate of Jerusalem – often referred to as Palestine – was a component. At the meeting David Lloyd George, then Chancellor of the Exchequer, "referred to the ultimate destiny of Palestine". The Chancellor, whose law firm Lloyd George, Roberts and Co had been engaged a decade before by the Zionist Federation of Great Britain and Ireland to work on the Uganda Scheme, was to become prime minister by the time of the declaration, and was ultimately responsible for it.
==== Sulfur and lightning ==== Sulfur’s role as a symbol of divine wrath and punishment may come from its association with lightning. For centuries, lightning was thought to cause a sulfur smell when it struck, and was therefore linked with it, including in religious contexts. In the 12th century, the Byzantine scholar John Tzetzes discussed the different associations around the word theion in his Chiliades, mentioning different meanings such as sulfur, incense (which he links to the breath of the immortals) and thunder, as well as it referring to "bewildering" and "amazing" things, the stars, souls, and angels. He explains that thunder is divine fire, and that it gives off a strong smell resembling sulfur. Lightning being sulfurous is a very ancient belief, mentioned by ancient Roman authors and present in the works of Homer, where descriptions of the divine lightning of Zeus mention sulfur several times (in the Iliad, it strikes in front of the horses of Diomedes, causing a smell of sulfur and flames, at another point, Hector is compared to an oak uprooted by Zeus' lightning, smelling of sulfur, while in the Odyssey, it strikes a ship, filling it with sulfurous smoke). The 18th century theologian Jonathan Edwards considered lightning to be "a string of brimstone". Lightning does not actually contain sulfur or produce sulfur odorants. Ozone would later be identified, in the 19th century, as the element behind the smell of lightning, but even then, people unfamiliar with ozone were said to still commonly misidentify the smell as brimstone.
=== Common properties === The various ribosomes share a core structure, which is quite similar despite the large differences in size. Much of the RNA is highly organized into various tertiary structural motifs, for example pseudoknots that exhibit coaxial stacking. The extra RNA in the larger ribosomes is in several long continuous insertions, such that they form loops out of the core structure without disrupting or changing it. All of the catalytic activity of the ribosome is carried out by the RNA; the proteins reside on the surface and seem to stabilize the structure.
== Treatment == Balloon syndrome is a very painful condition with the skin stretched tight and the air beneath compressing the organs, so the first treatment is pain relief. The hedgehog will be suffering from severe stress, being unable to curl into a ball and defend itself, so it must be treated quietly and as quickly as possible. A large gauge needle attached to a 3-way stopcock is used to aspirate the air. It is necessary to enter at several sites to release the air, as the space beneath the skin is compartmentalised by connective tissue, not one big space. The patient will be dehydrated and hungry, as the condition prevents the hedgehog reaching down to drink or eat. It is vital that the hedgehog be left to recover in appropriate surroundings, given food and water and antibiotic cover. The procedure may need repeating the following day, if more air accumulates.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.